Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: Results of a multicenter retrospective Italian study

Angiolo Gadducci, Enrico Sartori, Fabio Landoni, Paolo Zola, Tiziano Maggino, Angelo Maggioni, Stefania Cosio, Eleonora Frassi, Maria Teresa LaPresa, Luca Fuso, Renza Cristofani

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Purpose: To assess whether the interval from primary surgery to the start of taxane- plus platinum-based chemotherapy has any impact on the clinical outcome of advanced ovarian cancer patients. Patients and Methods: The study was conducted on 313 patients who underwent surgery followed by taxane- plus platinum-based chemotherapy. The median follow-up of survivors was 30.7 months (range, 6 to 109 months). Results: The 25%, 50%, and 75% quantiles of intervals from surgery to the start of chemotherapy were 11, 21, and 31 days, respectively. After the sixth cycle, 102 patients achieved a pathologic complete response at second-look surgery and 98 obtained a clinical complete response but were not submitted to second-look surgery. Taking into consideration the best assessed response, a complete (either clinical or pathologic) response was found in 200 patients. Residual disease (≤ 1 v > 1 cm; P <.0001) and ascites (absent v present; P = .003) were independent predictive factors for achieving a complete response, whereas residual disease (P = .001 ) and stage (IIc to III v IV; P = .04) were independent prognostic variables for survival. Conversely, statistical analyses failed to detect significant differences in complete response rates and survival among patients with an interval from surgery to chemotherapy shorter than 11 days, 12 to 21 days, 22 to 31 days, and longer than 31 days. Conclusion: The interval from surgery to the start of taxane- plus platinum-based chemotherapy seems to have neither a predictive value for response to treatment nor a prognostic relevance for survival of advanced ovarian cancer patients.

Original languageEnglish
Pages (from-to)751-758
Number of pages8
JournalJournal of Clinical Oncology
Volume23
Issue number4
DOIs
Publication statusPublished - 2005

Fingerprint

Platinum
Retrospective Studies
Drug Therapy
Second-Look Surgery
Ovarian Neoplasms
Survival
Ovarian epithelial cancer
taxane
Ascites
Survivors
Survival Rate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer : Results of a multicenter retrospective Italian study. / Gadducci, Angiolo; Sartori, Enrico; Landoni, Fabio; Zola, Paolo; Maggino, Tiziano; Maggioni, Angelo; Cosio, Stefania; Frassi, Eleonora; LaPresa, Maria Teresa; Fuso, Luca; Cristofani, Renza.

In: Journal of Clinical Oncology, Vol. 23, No. 4, 2005, p. 751-758.

Research output: Contribution to journalArticle

@article{7ea79a0c265c4cf8a5b86c1aaf7e2c1b,
title = "Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: Results of a multicenter retrospective Italian study",
abstract = "Purpose: To assess whether the interval from primary surgery to the start of taxane- plus platinum-based chemotherapy has any impact on the clinical outcome of advanced ovarian cancer patients. Patients and Methods: The study was conducted on 313 patients who underwent surgery followed by taxane- plus platinum-based chemotherapy. The median follow-up of survivors was 30.7 months (range, 6 to 109 months). Results: The 25{\%}, 50{\%}, and 75{\%} quantiles of intervals from surgery to the start of chemotherapy were 11, 21, and 31 days, respectively. After the sixth cycle, 102 patients achieved a pathologic complete response at second-look surgery and 98 obtained a clinical complete response but were not submitted to second-look surgery. Taking into consideration the best assessed response, a complete (either clinical or pathologic) response was found in 200 patients. Residual disease (≤ 1 v > 1 cm; P <.0001) and ascites (absent v present; P = .003) were independent predictive factors for achieving a complete response, whereas residual disease (P = .001 ) and stage (IIc to III v IV; P = .04) were independent prognostic variables for survival. Conversely, statistical analyses failed to detect significant differences in complete response rates and survival among patients with an interval from surgery to chemotherapy shorter than 11 days, 12 to 21 days, 22 to 31 days, and longer than 31 days. Conclusion: The interval from surgery to the start of taxane- plus platinum-based chemotherapy seems to have neither a predictive value for response to treatment nor a prognostic relevance for survival of advanced ovarian cancer patients.",
author = "Angiolo Gadducci and Enrico Sartori and Fabio Landoni and Paolo Zola and Tiziano Maggino and Angelo Maggioni and Stefania Cosio and Eleonora Frassi and LaPresa, {Maria Teresa} and Luca Fuso and Renza Cristofani",
year = "2005",
doi = "10.1200/JCO.2005.03.065",
language = "English",
volume = "23",
pages = "751--758",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer

T2 - Results of a multicenter retrospective Italian study

AU - Gadducci, Angiolo

AU - Sartori, Enrico

AU - Landoni, Fabio

AU - Zola, Paolo

AU - Maggino, Tiziano

AU - Maggioni, Angelo

AU - Cosio, Stefania

AU - Frassi, Eleonora

AU - LaPresa, Maria Teresa

AU - Fuso, Luca

AU - Cristofani, Renza

PY - 2005

Y1 - 2005

N2 - Purpose: To assess whether the interval from primary surgery to the start of taxane- plus platinum-based chemotherapy has any impact on the clinical outcome of advanced ovarian cancer patients. Patients and Methods: The study was conducted on 313 patients who underwent surgery followed by taxane- plus platinum-based chemotherapy. The median follow-up of survivors was 30.7 months (range, 6 to 109 months). Results: The 25%, 50%, and 75% quantiles of intervals from surgery to the start of chemotherapy were 11, 21, and 31 days, respectively. After the sixth cycle, 102 patients achieved a pathologic complete response at second-look surgery and 98 obtained a clinical complete response but were not submitted to second-look surgery. Taking into consideration the best assessed response, a complete (either clinical or pathologic) response was found in 200 patients. Residual disease (≤ 1 v > 1 cm; P <.0001) and ascites (absent v present; P = .003) were independent predictive factors for achieving a complete response, whereas residual disease (P = .001 ) and stage (IIc to III v IV; P = .04) were independent prognostic variables for survival. Conversely, statistical analyses failed to detect significant differences in complete response rates and survival among patients with an interval from surgery to chemotherapy shorter than 11 days, 12 to 21 days, 22 to 31 days, and longer than 31 days. Conclusion: The interval from surgery to the start of taxane- plus platinum-based chemotherapy seems to have neither a predictive value for response to treatment nor a prognostic relevance for survival of advanced ovarian cancer patients.

AB - Purpose: To assess whether the interval from primary surgery to the start of taxane- plus platinum-based chemotherapy has any impact on the clinical outcome of advanced ovarian cancer patients. Patients and Methods: The study was conducted on 313 patients who underwent surgery followed by taxane- plus platinum-based chemotherapy. The median follow-up of survivors was 30.7 months (range, 6 to 109 months). Results: The 25%, 50%, and 75% quantiles of intervals from surgery to the start of chemotherapy were 11, 21, and 31 days, respectively. After the sixth cycle, 102 patients achieved a pathologic complete response at second-look surgery and 98 obtained a clinical complete response but were not submitted to second-look surgery. Taking into consideration the best assessed response, a complete (either clinical or pathologic) response was found in 200 patients. Residual disease (≤ 1 v > 1 cm; P <.0001) and ascites (absent v present; P = .003) were independent predictive factors for achieving a complete response, whereas residual disease (P = .001 ) and stage (IIc to III v IV; P = .04) were independent prognostic variables for survival. Conversely, statistical analyses failed to detect significant differences in complete response rates and survival among patients with an interval from surgery to chemotherapy shorter than 11 days, 12 to 21 days, 22 to 31 days, and longer than 31 days. Conclusion: The interval from surgery to the start of taxane- plus platinum-based chemotherapy seems to have neither a predictive value for response to treatment nor a prognostic relevance for survival of advanced ovarian cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=20044379401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044379401&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.03.065

DO - 10.1200/JCO.2005.03.065

M3 - Article

C2 - 15613698

AN - SCOPUS:20044379401

VL - 23

SP - 751

EP - 758

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -